Eiger BioPharmaceuticals, Inc.
EIGR
Clasificación en acciones
#36445
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Precio por acción
$1.73
Última sincronización: 2025-06-17
Capitalización bursátil
$2.55M
Cambio (1 día)
-0.29%
Cambio (1 año)
-79.71%
País
US
Comercio Eiger BioPharmaceuticals, Inc. (EIGR)
Categoría
Healthcare
Historial de desdoblamientos de acciones de Eiger BioPharmaceuticals, Inc. (EIGR)
La acción Eiger BioPharmaceuticals, Inc. (símbolo: EIGR) tuvo un total de 2 desdoblamientos.
El desdoblamiento más reciente ocurrió el Jan 08, 2024.
Una acción EIGR comprada antes de Mar 23, 2016 equivaldría hoy a 0.0022222222222222 acciones EIGR.
El desdoblamiento más reciente ocurrió el Jan 08, 2024.
Una acción EIGR comprada antes de Mar 23, 2016 equivaldría hoy a 0.0022222222222222 acciones EIGR.
Lista de desdoblamientos de acciones
| Año | Desdoblamiento | Multiplicador | Multiplicador acumulado |
|---|---|---|---|
| 2024-01-08 | 1:30 | x0.033333333333333 | x0.0022222222222222 |
| 2016-03-23 | 1:15 | x0.066666666666667 | x0.066666666666667 |
Desdoblamientos de acciones de empresas similares o competidoras
| Empresa | Número de desdoblamientos de acciones | Multiplicador acumulado | País |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|